Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

Yazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medicine, 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, 3Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA Abstract: Chronic lymphoc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Madanat YF, Smith MR, Almasan A, Hill BT
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Idelalisib PI3Kδ inhibitors chronic lymphocytic leukemia follicular lymphoma Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/89d8c5e4fe2c4f3693441581fda438cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:89d8c5e4fe2c4f3693441581fda438cc
record_format	dspace
spelling	oai:doaj.org-article:89d8c5e4fe2c4f3693441581fda438cc2021-12-02T02:16:26ZIdelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas1179-9889https://doaj.org/article/89d8c5e4fe2c4f3693441581fda438cc2016-03-01T00:00:00Zhttps://www.dovepress.com/idelalisib-therapy-of-indolent-b-cell-malignancies-chronic-lymphocytic-peer-reviewed-article-BLCTThttps://doaj.org/toc/1179-9889Yazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medicine, 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, 3Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA Abstract: Chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma are indolent B-cell lymphoproliferative disorders that mainly affect an older population. Although the majority of patients in need of treatment derive significant benefit from conventional chemotherapeutic agents as well as monoclonal antibodies, less toxic and more effective treatments are needed. Novel agents that inhibit the B-cell receptor signaling pathway have shown promising outcomes in these disorders. Idelalisib is a potent selective oral inhibitor of phosphatidylinositol 3-kinase delta and has shown significant clinical activity in B-cell malignancies. In this review, we summarize the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of relapsed/refractory disease. The adverse effect profile includes autoimmune disorders such as transaminitis, colitis, and pneumonitis. Given the efficacy and manageable toxicity profile of idelalisib, it is being increasingly incorporated into the management of indolent B-cell malignancies. Keywords: idelalisib, PI3Kδ inhibitors, chronic lymphocytic leukemia, follicular lymphomaMadanat YFSmith MRAlmasan AHill BTDove Medical PressarticleIdelalisibPI3Kδ inhibitorschronic lymphocytic leukemiafollicular lymphomaDiseases of the blood and blood-forming organsRC633-647.5ENBlood and Lymphatic Cancer: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 1-6 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Idelalisib PI3Kδ inhibitors chronic lymphocytic leukemia follicular lymphoma Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Idelalisib PI3Kδ inhibitors chronic lymphocytic leukemia follicular lymphoma Diseases of the blood and blood-forming organs RC633-647.5 Madanat YF Smith MR Almasan A Hill BT Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
description	Yazan F Madanat,1 Mitchell R Smith,2 Alexandru Almasan,3 Brian T Hill2 1Department of Internal Medicine, 2Department of Hematology and Medical Oncology, Taussig Cancer Institute, 3Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA Abstract: Chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma are indolent B-cell lymphoproliferative disorders that mainly affect an older population. Although the majority of patients in need of treatment derive significant benefit from conventional chemotherapeutic agents as well as monoclonal antibodies, less toxic and more effective treatments are needed. Novel agents that inhibit the B-cell receptor signaling pathway have shown promising outcomes in these disorders. Idelalisib is a potent selective oral inhibitor of phosphatidylinositol 3-kinase delta and has shown significant clinical activity in B-cell malignancies. In this review, we summarize the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of relapsed/refractory disease. The adverse effect profile includes autoimmune disorders such as transaminitis, colitis, and pneumonitis. Given the efficacy and manageable toxicity profile of idelalisib, it is being increasingly incorporated into the management of indolent B-cell malignancies. Keywords: idelalisib, PI3Kδ inhibitors, chronic lymphocytic leukemia, follicular lymphoma
format	article
author	Madanat YF Smith MR Almasan A Hill BT
author_facet	Madanat YF Smith MR Almasan A Hill BT
author_sort	Madanat YF
title	Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
title_short	Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
title_full	Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
title_fullStr	Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
title_full_unstemmed	Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
title_sort	idelalisib therapy of indolent b-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/89d8c5e4fe2c4f3693441581fda438cc
work_keys_str_mv	AT madanatyf idelalisibtherapyofindolentbcellmalignancieschroniclymphocyticleukemiaandsmalllymphocyticorfollicularlymphomas AT smithmr idelalisibtherapyofindolentbcellmalignancieschroniclymphocyticleukemiaandsmalllymphocyticorfollicularlymphomas AT almasana idelalisibtherapyofindolentbcellmalignancieschroniclymphocyticleukemiaandsmalllymphocyticorfollicularlymphomas AT hillbt idelalisibtherapyofindolentbcellmalignancieschroniclymphocyticleukemiaandsmalllymphocyticorfollicularlymphomas
_version_	1718402607787016192

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

Ejemplares similares